WO2005093426A3 - Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) - Google Patents

Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) Download PDF

Info

Publication number
WO2005093426A3
WO2005093426A3 PCT/EP2005/002599 EP2005002599W WO2005093426A3 WO 2005093426 A3 WO2005093426 A3 WO 2005093426A3 EP 2005002599 W EP2005002599 W EP 2005002599W WO 2005093426 A3 WO2005093426 A3 WO 2005093426A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
rara
therapeutics
diagnostics
retinoic acid
Prior art date
Application number
PCT/EP2005/002599
Other languages
French (fr)
Other versions
WO2005093426A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005093426A2 publication Critical patent/WO2005093426A2/en
Publication of WO2005093426A3 publication Critical patent/WO2005093426A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human RARA which is associated with the cardiovascular diseases, infections, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, hematological diseases, respiratory diseases, inflammation, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, hematological diseases, respiratory diseases, inflammation, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of RARA as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/002599 2004-03-26 2005-03-11 Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) WO2005093426A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007432 2004-03-26
EP04007432.0 2004-03-26

Publications (2)

Publication Number Publication Date
WO2005093426A2 WO2005093426A2 (en) 2005-10-06
WO2005093426A3 true WO2005093426A3 (en) 2006-03-23

Family

ID=34980048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002599 WO2005093426A2 (en) 2004-03-26 2005-03-11 Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)

Country Status (1)

Country Link
WO (1) WO2005093426A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125749A2 (en) * 2011-03-14 2012-09-20 Io Therapeutics, Inc. INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248791B1 (en) * 1994-08-02 2001-06-19 Centre International De Recherches Dermatologiques Galderma Stimulating the differentiation of preadipocytic cells and therapies based thereon
WO2001074759A1 (en) * 2000-04-04 2001-10-11 Allergan, Inc. Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248791B1 (en) * 1994-08-02 2001-06-19 Centre International De Recherches Dermatologiques Galderma Stimulating the differentiation of preadipocytic cells and therapies based thereon
WO2001074759A1 (en) * 2000-04-04 2001-10-11 Allergan, Inc. Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia

Also Published As

Publication number Publication date
WO2005093426A2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2005093426A3 (en) Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2005101006A3 (en) Diagnostics and therapeutics for diseases associated with retinoid x receptor beta (rxrb)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2005118832A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase